Literature DB >> 19461510

Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis.

Ayse Ayhan1, Robert J Kurman, Anna Yemelyanova, Russell Vang, Sanjay Logani, Jeffrey D Seidman, Ie-Ming Shih.   

Abstract

A 2-tier grading system based on nuclear grade divides ovarian serous carcinomas into low (nuclear grade 1) and high grade (nuclear grade 3). In most instances the separation is straightforward but at times, the morphologic distinction between them can be difficult. We studied 11 ovarian serous carcinomas with features that were "intermediate" (nuclear grade 2) between low and high grade. All the cases were high staged and had a poor clinical outcome. None of the tumors showed mutations in KRAS, BRAF, and ERBB2 genes that characterize most low-grade serous carcinomas. In contrast, 10 (90.9%) of 11 cases contained nonsynonymous TP53 mutations characteristic of high-grade serous carcinomas. In summary, the molecular genetic profile and behavior of serous carcinomas with grade 2 nuclei are virtually the same as those of serous carcinomas with grade 3 nuclei, supporting the use of the 2-tier grading system for classifying ovarian serous carcinomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19461510      PMCID: PMC2716424          DOI: 10.1097/PAS.0b013e3181a24354

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  17 in total

1.  PIK3CA mutations in advanced ovarian carcinomas.

Authors:  Yun Wang; Aslaug Helland; Ruth Holm; Gunnar B Kristensen; Anne-Lise Børresen-Dale
Journal:  Hum Mutat       Date:  2005-03       Impact factor: 4.878

Review 2.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

3.  Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up.

Authors:  Y Shimizu; S Kamoi; S Amada; F Akiyama; S G Silverberg
Journal:  Cancer       Date:  1998-03-01       Impact factor: 6.860

4.  Classification and staging of malignant tumours in the female pelvis.

Authors: 
Journal:  Acta Obstet Gynecol Scand       Date:  1971       Impact factor: 3.636

5.  Mutation of the PIK3CA gene in ovarian and breast cancer.

Authors:  Ian G Campbell; Sarah E Russell; David Y H Choong; Karen G Montgomery; Marianne L Ciavarella; Christine S F Hooi; Briony E Cristiano; Richard B Pearson; Wayne A Phillips
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

6.  Diverse tumorigenic pathways in ovarian serous carcinoma.

Authors:  Gad Singer; Robert J Kurman; Hsueh-Wei Chang; Sarah K R Cho; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

7.  Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

Authors:  Gad Singer; Robert Oldt; Yoram Cohen; Brant G Wang; David Sidransky; Robert J Kurman; Ie-Ming Shih
Journal:  J Natl Cancer Inst       Date:  2003-03-19       Impact factor: 13.506

8.  Grading ovarian serous carcinoma using a two-tier system.

Authors:  Anais Malpica; Michael T Deavers; Karen Lu; Diane C Bodurka; Edward N Atkinson; David M Gershenson; Elvio G Silva
Journal:  Am J Surg Pathol       Date:  2004-04       Impact factor: 6.394

Review 9.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Authors:  Ie-Ming Shih; Robert J Kurman
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

10.  Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).

Authors:  Gad Singer; Ie-Ming Shih; Alexander Truskinovsky; Haldun Umudum; Robert J Kurman
Journal:  Int J Gynecol Pathol       Date:  2003-01       Impact factor: 2.762

View more
  25 in total

Review 1.  Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Authors:  Russell Vang; Ie-Ming Shih; Robert J Kurman
Journal:  Adv Anat Pathol       Date:  2009-09       Impact factor: 3.875

Review 2.  [Histological grading of epithelial ovarian cancer. Review and recommendation].

Authors:  S Hauptmann; A du Bois; I Meinhold-Herlein; J Pfisterer; S Avril
Journal:  Pathologe       Date:  2014-09       Impact factor: 1.011

3.  Comparison of candidate serologic markers for type I and type II ovarian cancer.

Authors:  Dan Lu; Elisabetta Kuhn; Robert E Bristow; Robert L Giuntoli; Susanne Krüger Kjær; Ie-Ming Shih; Richard B S Roden
Journal:  Gynecol Oncol       Date:  2011-06-24       Impact factor: 5.482

4.  Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.

Authors:  Chen Wang; Sebastian M Armasu; Kimberly R Kalli; Matthew J Maurer; Ethan P Heinzen; Gary L Keeney; William A Cliby; Ann L Oberg; Scott H Kaufmann; Ellen L Goode
Journal:  Clin Cancer Res       Date:  2017-03-09       Impact factor: 12.531

5.  An endogenous aryl hydrocarbon receptor ligand inhibits proliferation and migration of human ovarian cancer cells.

Authors:  Kai Wang; Yan Li; Yi-Zhou Jiang; Cai-Feng Dai; Manish S Patankar; Jia-Sheng Song; Jing Zheng
Journal:  Cancer Lett       Date:  2013-07-09       Impact factor: 8.679

6.  Expression and roles of Slit/Robo in human ovarian cancer.

Authors:  Cai Feng Dai; Yi Zhou Jiang; Yan Li; Kai Wang; Pei Shu Liu; Manish S Patankar; Jing Zheng
Journal:  Histochem Cell Biol       Date:  2011-04-05       Impact factor: 4.304

Review 7.  Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects.

Authors:  Jian-Jun Wei; Josette William; Serdar Bulun
Journal:  Int J Gynecol Pathol       Date:  2011-11       Impact factor: 2.762

Review 8.  Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features.

Authors:  Jaime Prat
Journal:  Virchows Arch       Date:  2012-02-10       Impact factor: 4.064

9.  Serous ovarian tumors: Immunohistochemical profiling as an aid to grading and understanding tumorigenesis.

Authors:  V Manu; Tin Aung Hein; Dibyajyoti Boruah; V Srinivas
Journal:  Med J Armed Forces India       Date:  2018-10-10

10.  Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis.

Authors:  Matthew Schwede; Dimitrios Spentzos; Stefan Bentink; Oliver Hofmann; Benjamin Haibe-Kains; David Harrington; John Quackenbush; Aedín C Culhane
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.